COMPUGEN LTD CGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
6/9
Piotroski F — financial health
-0.84
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $72.8M | $35.3M | $63.5M | $31.3M | $102.7M |
| 2024 | $27.9M | -$14.2M | $19.9M | $49.5M | $54.9M |
| 2023 | $33.5M | -$18.8M | $31.5M | -$36.1M | $65.6M |
| 2022 | $7.5M | -$33.7M | $6.5M | -$34.6M | $77.7M |
| 2021 | $6.0M | -$34.2M | $5.3M | -$23.0M | $106.7M |
| 2020 | $2.0M | -$29.7M | $1.9M | -$28.5M | $119.8M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.84 (distress)
- Working capital / assets 0.801
- Retained earnings / assets -2.896
- EBIT / assets 0.2
- Equity / liabilities 1.908
Source: SEC EDGAR filings · CIK 0001119774 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.